The size of the Pancreatic Cancer Market in the Middle East and Africa was worth USD 0.21 billion in 2022 and is estimated to be growing at a CAGR of 6.865 %, to reach USD 0.30 billion by 2027.
Pancreatic cancer is one of the most common cancers in males leading to death due to aggressive metastatic growth and complications. The presence of several risk factors with co-morbidities increases the incidence rate of pancreatic cancer. The overall pancreatic cancer death rate in Egypt was reported at 1.48 / 100,000 population, and analysis of the regional distribution showed significant variations in rates between provinces, with the northern provinces having higher rates than those in the southern. The cancer prevalence in Saudi Arabia is recorded at 2.25/100,000, with an annual death rate of 1.64/100,000. Based on these same reports, the majority in males is at 2.75/100,000 and 1.69/100,000 in women.
Advances in technology and medicine are opening up new opportunities for physicians and other healthcare providers to treat pancreatic cancer better. Early diagnosis and intervention are seen to have better results. According to one report, only 13% to 16% of patients are diagnosed early enough to be treated with surgery, drugs, and chemotherapy. Latest diagnostic tests and therapeutics modalities are helping to fight this cancer with fewer side effects. Increased alcohol use, obesity, drug addiction, and smoking, and the growing rate of the geriatric population will increase the rate of pancreatic cancer in the Middle East and African region.
However, several factors are responsible for hampering the market's growth rate. Factors such as the lack of healthcare facilities, limited treatment options, absence of whole coverage insurance policies, and low success rates in clinical trials of cancer drugs will be responsible for restraining the market in the years to come. Moreover, the poor economic status of developing and developing regions in the MEA region challenges the growth of the MEA pancreatic cancer market.
This research report on the MEA pancreatic cancer market has been segmented & sub-segmented into the following categories:
By Treatment Type:
By Cancer Type:
By End User:
Geographically, the MEA pancreatic cancer treatment market is estimated to post commendable gains by the end of 2027, mainly dominated by the revenues generated in Saudi Arabia, the United Arab Emirate, followed by Qatar.
In 2020, the Saudi Arabian regional market had experienced respectable growth in the Middle East and Africa pancreatic cancer market. This regional market growth can be attributed to increased funds for research and development, supportive reimbursement policies, and the presence of technologically advanced diagnostic and treatment options to tackle this aggrieve type of cancer. In addition, supportive government activities in the form of campaigns, camps, surveys, and studies raise awareness about pancreatic cancer among the Saudi Arabian population in the years to come.
The unmet market demand related to the disease drives many multinational companies to invest in the African region. In addition, the large patient population, public awareness of the disease and symptoms, and the continued efforts by regional authorities will drive the market in this region, especially in South Africa.
Qatar and the United Arab Emirates are predicted to post a healthy growth rate during the forecast period. Factors such as improving healthcare infrastructure, growing demand for high-quality healthcare, and increased expenditure are estimated to boost the CAGR during the forecasted period.
KEY MARKET PLAYERS:
Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., and NewLink Genetics Corp. are playing a leading role in the MEA Pancreatic Cancer Market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]